DUBLIN--(BUSINESS WIRE)--The "Royalty Rates in Pharmaceutical and Biotechnology Deals" report has been added to ResearchAndMarkets.com's offering. Royalty Rates in Pharmaceutical and Biotechnology ...

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG ("Araris") today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) ...

F rom blockbuster drugs that garner media attention to smaller innovations that help millions maintain health, the biotech and pharmaceutical industries have an impact on everyone’s life. Meanwhile, ...

In the competitive pharmaceutical and biotechnology industries, where robust patent portfolios are essential for protecting innovative biologics and enabling successful biosimilar development and ...

By Puyaan Singh April 27 (Reuters) - Ligand Pharmaceuticals will buy fellow biotechnology royalty aggregator XOMA Royalty for ...

Biotech stocks may offer your portfolio an element of growth, and that's because these companies are sharply focused on innovation. They set out to tackle some of the most challenging diseases, and as ...

AbbVie has agreed to pay $30 million upfront to Haisco Pharmaceutical Group for ex-China rights to two non-opioid pain treatment candidates. | AbbVie has agreed to pay $30 million upfront to Chinese ...

State Key Laboratory of Pharmaceutical Biotechnology, HKU has the following research output in the current window (1 January 2025 - 31 December 2025) of the Nature Index. Click on Count to view a list ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Synthekine Inc., an engineered cytokine therapeutics company, today announced the appointment of John A. Orwin as Chair of its Board of Directors. Mr. Orwin ...

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.

The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...

April 27 (Reuters) - Ligand Pharmaceuticals will buy fellow biotechnology royalty aggregator XOMA Royalty for about $739 million in cash, the companies said on Monday. The deal adds more than 120 ...